AdaptHealth price target raised to $21 from $20 at Baird

Baird analyst Eric Coldwell raised the firm’s price target on AdaptHealth to $21 from $20 and keeps an Outperform rating on the shares. The firm said we see a lot to like big picture including strong Sleep performance, early cost management program results, a significant VBC partnership, and a new CEO to steer the ship in right direction.